Christopher Mutz - 12 Feb 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Role
HEAD OF RARE DISEASE
Signature
/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook
Issuer symbol
ANIP
Transactions as of
12 Feb 2026
Net transactions value
-$967,565
Form type
4
Filing time
17 Feb 2026, 16:08:03 UTC
Previous filing
13 Feb 2026
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mutz Christopher HEAD OF RARE DISEASE C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE /s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook 17 Feb 2026 0001846487

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIP Common Stock Tax liability $243,369 -3,173 -3.1% $76.70 99,598 12 Feb 2026 Direct F1
transaction ANIP Common Stock Sale $538,300 -7,032 -7.1% $76.55 92,566 12 Feb 2026 Direct F2, F3
transaction ANIP Common Stock Tax liability $185,896 -2,403 -2.6% $77.36 90,163 14 Feb 2026 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
F3 The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price.
F4 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported on February 16, 2024.